Invention Grant
- Patent Title: Antibodies targeting CD137 and methods of use thereof
-
Application No.: US16754097Application Date: 2018-10-09
-
Publication No.: US11578133B2Publication Date: 2023-02-14
- Inventor: Tea Gunde , Matthias Brock , Christian Hess , Alexandre Simonin
- Applicant: Numab Therapeutics AG
- Applicant Address: CH Wädenswil
- Assignee: Numab Therapeutics AG
- Current Assignee: Numab Therapeutics AG
- Current Assignee Address: CH Wädenswil
- Agency: Prismatic Law Group, PLLC
- Agent Ron Kamis
- Priority: EP17195780 20171010,EP18167092 20180412,EP18180815 20180629
- International Application: PCT/EP2018/077514 WO 20181009
- International Announcement: WO2019/072870 WO 20190418
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
Public/Granted literature
- US20200332015A1 ANTIBODIES TARGETING CD137 AND METHODS OF USE THEREOF Public/Granted day:2020-10-22
Information query
